Michael Lee, OD
Optometry · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lee’s office at (408) 972-3413 to ask if they take your plan before you enroll.
Medicaid work
$0 in 2019
Medicaid paid $0 for 15 billed services this clinician did in 2019, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| DETERMINATION REFRACTIVE STATE | 15 | $0 |
| 2019 | 15 | 1 | 15 | $0 |
| 2018 | 127 | 3 | 21 | $0 |
See the largest Medicaid services in earlier years
2018
| INTRM OPH EXAM NEW PATIENT | 16 | $0 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 27 | $0 |
| DETERMINATION REFRACTIVE STATE | 84 | $0 |
Drugs they prescribed that Part D paid
$16,110
Pharmacies billed $16,110 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 146) in 2024. At or below the middle of the specialty; the typical optometry clinician is at 0%.
76 generic and 70 brand-name prescriptions · $16,110 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xiidra | 12 | $9,345 | $779 |
| Cyclosporine | 54 | $5,461 | $101 |
| Latanoprost | 32 | $361 | $11 |
Year by year
| 2024 | 146 | 48 | 0% (0) | 48% | $16,110 |
| 2023 | 189 | 81 | 0% (0) | 24% | $7,621 |
| 2022 | 177 | 77 | 0% (0) | 16% | $11,472 |
| 2021 | 190 | 74 | 0% (0) | 24% | $22,178 |
| 2020 | 130 | 51 | 0% (0) | 30% | $20,295 |
| 2019 | 96 | 47 | 0% (0) | 33% | $14,920 |
| 2018 | 83 | 49 | 0% (0) | 37% | $14,610 |
| 2017 | 136 | 30 | 0% (0) | 38% | $20,916 |
| 2016 | 216 | 48 | 0% (0) | 53% | $33,953 |
| 2015 | 378 | 66 | 0% (0) | 57% | $60,057 |
| 2014 | 377 | 93 | 0% (0) | 47% | $48,008 |
| 2013 | 329 | 97 | None | 61% | $36,616 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Cyclosporine | 45 | $4,968 | $110 |
| Olopatadine | 83 | $1,678 | $20 |
| Latanoprost | 28 | $313 | $11 |
2022: 4 drugs
| Cequa | 15 | $6,945 | $463 |
| Olopatadine | 113 | $2,147 | $19 |
| Cyclosporine | 11 | $1,705 | $155 |
| Latanoprost | 25 | $336 | $13 |
2021: 3 drugs
| Cequa | 39 | $17,562 | $450 |
| Olopatadine | 106 | $1,431 | $13 |
| Latanoprost | 15 | $255 | $17 |
2020: 2 drugs
| Restasis | 24 | $15,102 | $629 |
| Olopatadine | 66 | $1,080 | $16 |
2019: 2 drugs
| Restasis | 22 | $12,846 | $584 |
| Olopatadine | 49 | $792 | $16 |
2018: 2 drugs
| Restasis | 19 | $10,161 | $535 |
| Olopatadine | 32 | $344 | $11 |
2017: 2 drugs
| Restasis | 17 | $7,769 | $457 |
| Timolol Maleate | 21 | $602 | $29 |
2016: 7 drugs
| Restasis | 34 | $14,794 | $435 |
| Travatan Z | 20 | $4,438 | $222 |
| Lumigan | 18 | $4,167 | $231 |
| Brimonidine | 16 | $2,449 | $153 |
| Latanoprost | 27 | $426 | $16 |
| Timolol Maleate | 33 | $370 | $11 |
| Cromolyn | 14 | $122 | $9 |
2015: 9 drugs
| Restasis | 64 | $30,294 | $473 |
| Lumigan | 50 | $9,589 | $192 |
| Alphagan P | 32 | $5,794 | $181 |
| Travatan Z | 31 | $5,523 | $178 |
| Patanol | 13 | $3,062 | $236 |
| Latanoprost | 47 | $825 | $18 |
| Timolol Maleate | 51 | $417 | $8 |
| Brimonidine | 11 | $371 | $34 |
| Cromolyn | 30 | $266 | $9 |
2014: 6 drugs
| Restasis | 73 | $31,254 | $428 |
| Lumigan | 44 | $6,033 | $137 |
| Travatan Z | 21 | $3,336 | $159 |
| Latanoprost | 55 | $731 | $13 |
| Timolol Maleate | 60 | $598 | $10 |
| Cromolyn | 42 | $569 | $14 |
2013: 8 drugs
| Restasis | 45 | $15,318 | $340 |
| Lumigan | 43 | $6,743 | $157 |
| Travatan Z | 42 | $6,276 | $149 |
| Cromolyn | 44 | $752 | $17 |
| Latanoprost | 21 | $466 | $22 |
| Timolol Maleate | 28 | $302 | $11 |
| Naphazoline | 14 | $102 | $7 |
| Metoprolol | 13 | $74 | $6 |
Money from drug and device companies
$34 in 2020
A payment is not proof that care is biased.
| Carl Zeiss Meditec | None Specified | $34 | 2 payments
|
See all 2 published payments
| Carl Zeiss Meditec | Gift · 2020-05-14 | None Specified | $17 |
| Carl Zeiss Meditec | Gift · 2020-05-14 | None Specified | $17 |
Professional record
- NPI
- 1891013819
- Licence
- CA 13608T
- Trained
- University of California - School of Optometry, 2008
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 152W00000X (152W00000X)
- Mailing address
- 800 S Abel St Unit 305, Milpitas, CA, 95035
- NPI first listed
- 2010-05-14
- NPI last updated
- 2022-01-03
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.